Tesamorelin

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It binds with receptors in the pituitary gland and stimulates the release of growth hormone. It is composed of 44 amino acids and a trans-3-hexenoic acid group, which makes it more stable and extends its half-life as compared to endogenous GHRH.

It was first developed by a Canadian company named Theratechnologies Inc. for the treatment of lipodystrophy. FDA approved it for the treatment of HIV-associated lipodystrophy in 2010. Currently, it has been researched for its effect on the cardiovascular system and peripheral nerve damage. On our website, tesamorelin for sale is limited to research and educational purposes.

From Pubchem

 

Molecular Formula: C216H360N72O63S
Molecular Weight: 5006 g/mol
Sequence: YADAXFXNSYRKVLGQLSARKLLQDXMSRQQGQSNQRGARARL
CAS number: 218949-48-5
PubChem CID: 56928011

1. Tesamorelin and HIV-associated Lipodystrophy

Tesamorelin has already been approved by the FDA for the treatment of HIV-associated lipodystrophy. The antiretroviral therapy and HIV infection itself cause significant changes in body composition, including fat distribution. Lipodystrophy is characterized by excessive visceral adipose tissue in the abdomen, trunk and breast. It also causes loss of visceral adipose tissue in the face, arms, legs and buttocks.

Further, the accumulation of visceral adipose tissue is linked with insulin resistance and increased risk of heart disease and diabetes mellitus [1]. FDA-approved human recombinant growth hormone for the management of lipodystrophy. But it requires large doses that can cause further complications, including peripheral edema and carpal tunnel syndrome. On the other hand, tesamorelin is a safe and effective option for managing fat accumulation.

In a randomized controlled phase three trial, HIV patients with central obesity received either tesamorelin or a placebo for 26 weeks. After that, patients on tesamorelin were randomly switched to tesamorelin or placebo and the control group was switched to tesamorelin. The results found that a change in visceral adipose tissue was sustained during the course of the research. However, researchers observed reaccumulation of fat when tesamorelin was discontinued [2].

2. Tesamorelin in cardiovascular diseases

People with HIV are more likely to develop cardiovascular disease due to increased belly fat and the side effects of antiretroviral medications. Cardiovascular disease prevention is the most important medical intervention for HIV-positive patients after antiretroviral therapy.

Tesamorelin has been demonstrated to lower triglyceride, total, and non-HDL-C levels in HIV-positive patients in addition to reducing lipodystrophy. It was discovered that tesamorelin drastically decreased subcutaneous adipose tissue (body fat) by 15%[3].

3. Tesamorelin and Dementia

According to studies, GHRH analogues like tesamorelin may help patients with moderate cognitive impairment by enhancing their cognitive function.

Tesamorelin might boost levels of several neurotransmitters in the brain that are linked to the prevention and treatment of cognitive decline by increasing gamma-aminobutyric acid (GABA), [4].

4. Tesamorelin and Peripheral Nerve Damage

Peripheral nerve damage can occur because of multiple reasons, including diabetes, injury or surgical interventions. It can affect a person's ability to control movements and result in loss of sensory function. Nerve cells are difficult to regenerate, so there are not many therapies.

Research shows that growth hormone-based therapies might have the potential to speed up the regeneration of axons [5]. Axonal regeneration is important as it helps neurons to reach distal targets. Tesamorelin might help in restoring nerve damage. Clinical trials are ongoing to assess its effectiveness for peripheral nerve damage.

5. Current status of Tesamorelin

Tesamorelin has already been approved for the treatment of HIV-associated dystrophy. It is currently being examined for its potential to lessen cardiovascular disease in HIV patients, enhance the recovery of injured peripheral nerves, and decrease the course of dementia. Many other clinical trials are already in progress.

Tesamorelin has very few adverse effects, limited oral bioavailability, and great subcutaneous absorption. At Element Sarms, tesamorelin purchase is available for research purposes only. Only buy Tesamorelin if you are an authorized researcher.

1. Bedimo, R., Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl), 2011. 3: p. 69-79.
2. Falutz, J., et al., Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. Aids, 2008. 22(14): p. 1719-28.
3. Stanley, T.L., et al., Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical infectious diseases, 2012. 54(11): p. 1642-1651.
4. Friedman, S.D., et al., Growth Hormone–Releasing Hormone effects on brain γ-Aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA neurology, 2013. 70(7): p. 883-890.
5. Tuffaha, S.H., et al., Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert Opinion on Therapeutic Targets, 2016. 20(10): p. 1259-1265.